(Q37481264)

20 August 2017

1 reference

title

Trk kinase inhibitors as new treatments for cancer and pain (English)

1 reference

20 August 2017

Tao Wang

1

1 reference

20 August 2017

Dingwei Yu

series ordinal

2

1 reference

20 August 2017

Michelle L Lamb

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

305-319

1 reference

Protein kinases--the major drug targets of the twenty-first century?

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Trk receptors: mediators of neurotrophin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Trk receptor tyrosine kinases: a bridge between cancer and neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Manipulation of the nerve growth factor network in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Rational basis for Trk inhibition therapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Neuroblastoma: biological insights into a clinical enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Congenital insensitivity to pain with anhidrosis (CIPA): novel mutations of the TRKA (NTRK1) gene, a putative uniparental disomy, and a linkage of the mutant TRKA and PKLR genes in a family with CIPA and pyruvate kinase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Neurotrophins: mediators and modulators of pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Novel class of pain drugs based on antagonism of NGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Acute pancreatitis results in referred mechanical hypersensitivity and neuropeptide up-regulation that can be suppressed by the protein kinase inhibitor k252a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

The conformational plasticity of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on trkA tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Drug-target residence time and its implications for lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Molecular basis of neurotrophin-receptor interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902721261

10.1517/13543770902721261

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference